POSITIVE IN VITRO DATA FOR CHM 1301 CAR NK CELLS IN OVARIAN AND
PANCREATIC CANCERS
Positive preclinical data for CHM 1301, a next generation off the shelf CLTX CAR NK cell therapy
Up to 300% enhanced cell killing demonstrated compared to first generation NK cells
Evidence of expansion into two new solid tumours – pancreatic cancer and ovarian cancer
CHM 1301 program to advance to the next stage of preclinical development under academic
research collaboration
Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-2
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.76M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $9.531K | 515.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1853294 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| CHM (ASX) Chart |